What is the recommended initial treatment for a stuck mechanical mitral valve prosthesis due to suspected prosthetic‑valve thrombosis, and how should streptokinase be administered if tissue‑type plasminogen activator is unavailable?

Management of Stuck Mechanical Mitral Valve with Streptokinase

For a stuck mechanical mitral valve due to prosthetic valve thrombosis, when tissue-type plasminogen activator is unavailable, administer streptokinase 250,000 U bolus over 30 minutes followed by 100,000 U/hour continuous infusion, with treatment duration guided by serial echocardiography every 2-3 hours until hemodynamic improvement or up to 72 hours maximum. 1

Initial Assessment and Risk Stratification

Before initiating any therapy, confirm the diagnosis with urgent multimodality imaging including transthoracic and transesophageal echocardiography to assess valve gradients, leaflet motion, and thrombus size 2. The treatment decision hinges on:

• NYHA functional class (Class III-IV favors consideration of thrombolysis if surgical risk is high) 1
• Thrombus size (≤0.8 cm² favors thrombolysis; >0.8 cm² increases risk) 2
• Surgical risk and availability (high surgical risk or unavailable expertise favors thrombolysis) 1, 3
• Contraindications to thrombolysis (see below) 1

When to Choose Streptokinase Over Surgery

Thrombolysis with streptokinase should be considered for:

• Critically ill patients (NYHA Class III-IV) who are unlikely to survive surgery due to comorbidities or severely impaired cardiac function 1
• Situations where surgery is not immediately available and the patient cannot be transferred 1
• First-time valve thrombosis with small thrombus burden 2, 3
• High or prohibitive surgical risk 3, 4

Emergency surgery is preferred for:

• NYHA Class IV with acute pulmonary edema or cardiogenic shock 2
• Large thrombus burden >0.8 cm² 2
• Recurrent valve thrombosis despite prior therapy 2, 4
• Suspected pannus ingrowth rather than pure thrombus 2
• Absolute contraindications to thrombolysis 1, 3

Streptokinase Administration Protocol

Standard Dosing Regimen

Loading dose: 250,000 U administered over 30 minutes 1

Maintenance infusion: 100,000 U/hour continuous infusion 1

Duration: Continue until hemodynamic improvement (pressure gradient and valve area return to normal or near-normal) or for a maximum of 72 hours 1

Important Considerations

• Do NOT administer unfractionated heparin concurrently with streptokinase (unlike rt-PA protocols) 1
• For hemodynamically unstable patients, the European Society of Cardiology recommends a rapid protocol: streptokinase 1,500,000 U over 60 minutes without UFH 1, 3
• Slow infusion (15-24 hours) has similar success rates to rapid infusion (3 hours) but with significantly fewer major complications 5

Alternative if Streptokinase is Contraindicated

If the patient has previous exposure to streptokinase (causing antibody formation) or known allergy, use urokinase 4,400 U/kg/hour as per pulmonary embolism protocols 1, 3

Monitoring During Thrombolysis

Perform Doppler echocardiography every 2-3 hours to assess hemodynamic response 1

Stop thrombolytic infusion when:

• Pressure gradient and valve area normalize or near-normalize 1
• No hemodynamic improvement occurs at 24 hours 1
• Maximum duration of 72 hours is reached, even without complete recovery 1

Repeat transesophageal echocardiography at 24,48, and 72 hours if thrombus persists 1

Absolute Contraindications to Thrombolysis

Do not administer streptokinase if:

• Active internal bleeding 1, 3
• History of hemorrhagic stroke 1, 3
• Recent cranial trauma or neoplasm 1, 3
• Blood pressure >200/120 mmHg 1, 3
• Diabetic hemorrhagic retinopathy 1, 3

Relative Contraindications

Exercise caution with:

• Large thrombus in left atrium or on prosthesis 1, 3
• Infective endocarditis 1, 3
• Recent (<10 days) gastrointestinal bleeding 1
• Recent (<2 months) non-hemorrhagic stroke 1
• Uncontrolled severe hypertension 1, 3
• Previous exposure to streptokinase (use urokinase instead) 1, 3

Expected Outcomes and Success Rates

Success rates with streptokinase:

• Initial success after first dose: 53% 5
• Success after repeated sessions: 88% 5
• Overall success with recombinant streptokinase: 85.3% total response 6

Complication rates:

• Major hemorrhagic complications: approximately 3% 6
• Embolic events: 5-18% 6, 7
• Mortality: 1.9-5.9% 8, 6

Note: Rapid infusion protocols carry higher complication rates than slow infusion protocols 5

Critical Pitfalls to Avoid

Do not use streptokinase in patients with previous streptokinase exposure due to antibody formation—switch to urokinase 1, 3

Do not delay treatment while seeking additional imaging in hemodynamically unstable patients 2

Do not assume all prosthetic valve obstruction is thrombus—pannus ingrowth mimics obstruction but mandates surgical management 2

Do not use rapid infusion protocols when slow infusion is feasible, as major complications occur only with rapid infusion 5

Do not stop monitoring prematurely—serial echocardiography is mandatory to guide treatment duration 1

Post-Thrombolysis Management

After successful thrombolysis, repeat echocardiography to confirm resolution of obstruction and restoration of normal valve function 2

Optimize long-term anticoagulation with therapeutic INR maintenance (target INR 3.0 for mechanical mitral valves) and frequent monitoring 4

Consider adding low-dose aspirin to warfarin for all mechanical valves to prevent recurrence 4

Monitor for rethrombosis, which occurs in approximately 16% of cases but can be successfully retreated with thrombolysis 6